Pharmacologic stimulation of Cytochrome P450 46A1 and Cerebral Cholesterol Turnover in Mice

Journal of Biological Chemistry

Volumn 289, Issue 6, 2014, Pages 3529-3538

  Mast, Natalia ^a   Li, Yong ^a   Linger, Marlin ^a   Clark, Matthew ^b,c   Wiseman, Jeffrey ^c,d   Pikuleva, Irina A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pharmatrope Ltd   (United States)

^c ELSEVIER MASSON   (France)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BRAIN METABOLISM; CHOLESTEROL; CHOLESTEROL METABOLISM; CYTOCHROME P450;

ALZHEIMER DISEASE; ANIMALS; BENZOXAZINES; BRAIN; BRAIN CHEMISTRY; CATTLE; CHOLESTEROL; ENZYME ACTIVATION; FEMALE; HIV INFECTIONS; MALE; MICE; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE INHIBITORS; STEROID HYDROXYLASES;

EID: 84893682384     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.532846     Document Type: Article

References (50)

1. Russell, D. W., Halford, R. W., Ramirez, D. M., Shah, R., and Kotti, T. (2009) Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 78, 1017-1040
2. Ramirez, D. M., Andersson, S., and Russell, D. W. (2008) Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J. Comp. Neurol. 507, 1676-1693
3. Björkhem, I. (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260, 493-508
4. Meaney, S., Bodin, K., Diczfalusy, U., and Björkhem, I. (2002) On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J. Lipid Res. 43, 2130-2135
5. Babiker, A., and Diczfalusy, U. (1998) Transport of side-chain oxidized oxysterols in the human circulation. Biochim. Biophys. Acta 1392, 333-339
6. Björkhem, I., Lütjohann, D., Diczfalusy, U., Stahle, L., Ahlborg, G., and Wahren, J. (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39, 1594-1600
7. Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., and Russell, D. W. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980-22988
8. Kotti, T. J., Ramirez, D. M., Pfeiffer, B. E., Huber, K. M., and Russell, D. W. (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. U.S.A. 103, 3869-3874
9. Shafaati, M., Olin, M., Bavner, A., Pettersson, H., Rozell, B., Meaney, S., Parini, P., and Björkhem, I. (2011) Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. J. Intern. Med. 270, 377-387
10. Maioli, S., Bavner, A., Ali, Z., Heverin, M., Ismail, M. A., Puerta, E., Olin, M., Saeed, A., Shafaati, M., Parini, P., Cedazo-Minguez, A., and Björkhem, I. (2013) Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain? PLoS ONE 8, e68534
11. Hudry, E., Van Dam, D., Kulik, W., De Deyn, P. P., Stet, F. S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougnéres, P., Aubourg, P., and Cartier, N. (2010) Adeno-Associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18, 44-53
12. Bryleva, E. Y., Rogers, M. A., Chang, C. C., Buen, F., Harris, B. T., Rousselet, E., Seidah, N. G., Oddo, S., LaFerla, F. M., Spencer, T. A., Hickey, W. F., and Chang, T. Y. (2010) ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. U.S.A. 107, 3081-3086
13. Lund, E. G., Guileyardo, J. M., and Russell, D. W. (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U.S.A. 96, 7238-7243
14. Mast, N., White, M. A., Björkhem, I., Johnson, E. F., Stout, C. D., and Pikuleva, I. A. (2008) Crystal structures of substrate-bound and substratefree cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. U.S.A. 105, 9546-9551
15. Mast, N., Charvet, C., Pikuleva, I. A., and Stout, C. D. (2010) Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J. Biol. Chem. 285, 31783-31795
16. Mast, N., Linger, M., Clark, M., Wiseman, J., Stout, C. D., and Pikuleva, I. A. (2012) In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine. Mol. Pharmacol. 82, 824-834
17. White, M. A., Mast, N., Björkhem, I., Johnson, E. F., Stout, C. D., and Pikuleva, I. A. (2008) Use of complementary cation and anion heavy-Atom salt derivatives to solve the structure of cytochrome P450 46A1. Acta Crystallogr. D. Biol. Crystallogr. 64, 487-495
18. Mast, N., Reem, R., Bederman, I., Huang, S., DiPatre, P. L., Björkhem, I., and Pikuleva, I. A. (2011) Cholestenoic acid is an important elimination product of cholesterol in the retina: comparison of retinal cholesterol metabolism with that in the brain. Invest. Ophthalmol. Vis. Sci. 52, 594-603
19. Mast, N., Andersson, U., Nakayama, K., Björkhem, I., and Pikuleva, I. A. (2004) Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N-And C-terminal modifications. Arch. Biochem. Biophys. 428, 99-108
20. Mast, N., Zheng, W., Stout, C. D., and Pikuleva, I. A. (2013) Binding of a cyano-And fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response. J. Biol. Chem. 288, 4613-4624
21. Clark, M., Meshkat, S., Talbot, G. T., Carnevali, P., and Wiseman, J. S. (2009) Fragment-based computation of binding free energies by systematic sampling. J. Chem. Inf. Model. 49, 1901-1913
22. Mast, N., Shafaati, M., Zaman, W., Zheng, W., Prusak, D., Wood, T., Ansari, G. A., Lövgren-Sandblom, A., Olin, M., Björkhem, I., and Pikuleva, I. (2010) Marked variability in hepatic expression of cytochromes CYP7A1 and CYP27A1 as compared to cerebral CYP46A1. Lessons from a dietary study with omega 3 fatty acids in hamsters. Biochim. Biophys. Acta 1801, 674-681
23. Dzeletovic, S., Breuer, O., Lund, E., and Diczfalusy, U. (1995) Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225, 73-80
24. Wang, M., Heo, G.-Y., Omarova, S., Pikuleva, I. A., and Turko, I. V. (2012) Sample prefractionation for mass spectrometry quantification of low-Abundance membrane proteins. Anal. Chem. 84, 5186-5191
25. Schenkman, J. B., and Jansson, I. (2006) Spectral analyses of cytochromes P450. Methods Mol. Biol. 320, 11-18
26. Remmer, H., Schenkman, J., Estabrook, R. W., Sasame, H., Gillette, J., Narasimhulu, S., Cooper, D. Y., and Rosenthal, O. (1966) Drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 2, 187-190
27. Schenkman, J. B., Remmer, H., and Estabrook, R. W. (1967) Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 3, 113-123
28. Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) High-resolution crystal structure of cytochrome P450cam. J. Mol. Biol. 195, 687-700
29. Dawson, J. H., Andersson, L. A., and Sono, M. (1982) Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme. J. Biol. Chem. 257, 3606-3617
30. Poulos, T. L., and Howard, A. J. (1987) Crystal structures of metyraponeand phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 26, 8165-8174
31. Gigon, P. L., Gram, T. E., and Gillette, J. R. (1968) Effect of drug substrates on the reduction of hepatic microsomal cytochrome P-450 by NADPH. Biochem. Biophys. Res. Commun. 31, 558-562
32. Weiss, J. N. (1997) The Hill equation revisited: uses and misuses. FASEB J. 11, 835-841
33. Lund, E., Sisfontes, L., Reihner, E., and Björkhem, I. (1989) Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand. J. Clin. Lab. Invest. 49, 165-171
34. Häberle, J. (2011) Role of carglumic acid in the treatment of acute hyperammonemia due to N-Acetylglutamate synthase deficiency. Ther. Clin. Risk Manag. 7, 327-332
35. Matschinsky, F. M., Zelent, B., Doliba, N. M., Kaestner, K. H., Vanderkooi, J. M., Grimsby, J., Berthel, S. J., and Sarabu, R. (2011) Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb. Exp. Pharmacol. 203, 357-401
36. Blum, C. A., Ellis, J. L., Loh, C., Ng, P. Y., Perni, R. B., and Stein, R. L. (2011) SIRT1 modulation as a novel approach to the treatment of diseases of aging. J. Med. Chem. 54, 417-432
37. Treisman, G. J., and Kaplin, A. I. (2002) Neurologic and psychiatric complications of antiretroviral agents. AIDS 16, 1201-1215
38. Dietschy, J. M., and Turley, S. D. (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375-1397
39. Repa, J. J., Li, H., Frank-Cannon, T. C., Valasek, M. A., Turley, S. D., Tansey, M. G., and Dietschy, J. M. (2007) Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 27, 14470-14480
40. Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-Van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J., Steinbusch, H., Prickaerts, J., Lütjohann, D., and Mulder, M. (2011) Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 32, 1262-1272
41. Cao, G., Liang, Y., Jiang, X. C., and Eacho, P. I. (2004) Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect. 17, 35-41
42. Ohyama, Y., Meaney, S., Heverin, M., Ekström, L., Brafman, A., Shafir, M., Andersson, U., Olin, M., Eggertsen, G., Diczfalusy, U., Feinstein, E., and Björkhem, I. (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1). Marked insensitivity toward different regulatory axes. J. Biol. Chem. 281, 3810-3820
43. Liao, W.-L., Heo, G.-Y., Dodder, N. G., Reem, R. E., Mast, N., Huang, S., DiPatre, P. L., Turko, I. V., and Pikuleva, I. A. (2011) Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain. J. Proteome Res. 10, 241-248
44. Vanmierlo, T., Bloks, V. W., van Vark-van der Zee, L. C., Rutten, K., Kerksiek, A., Friedrichs, S., Sijbrands, E., Steinbusch, H. W., Kuipers, F., Lütjohann, D., and Mulder, M. (2010) Alterations in brain cholesterol metabolism in the APPSLxPS1mut mouse, a model for Alzheimer's disease. J. Alzheimers Dis. 19, 117-127
45. Bachmann, K., Patel, H., Batayneh, Z., Slama, J., White, D., Posey, J., Ekins, S., Gold, D., and Sambucetti, L. (2004) PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol. Res. 50, 237-246
46. Faucette, S. R., Zhang, T. C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., and Wang, H. (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80
47. Tohyama, J., Billheimer, J. T., Fuki, I. V., Rothblat, G. H., Rader, D. J., and Millar, J. S. (2009) Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis 204, 418-423
48. Gotti, D., Cesana, B. M., Albini, L., Calabresi, A., Izzo, I., Focá, E., Motta, D., Bellagamba, R., Fezza, R., Narciso, P., Sighinolfi, L., Maggi, P., Brianese, N., Quiros-Roldan, E., Guaraldi, G., and Torti, C. (2012) Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naive patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin. Trials 13, 245-255
49. Mast, N., Liao, W.-L., Pikuleva, I. A., and Turko, I. V. (2009) Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPHcytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 483, 81-89
50. Mast, N., Zheng, W., Stout, C. D., and Pikuleva, I. A. (2013) Antifungal azoles: structural insights into undesired tight binding to cholesterol- metabolizing CYP46A1. Mol. Pharmacol. 84, 86-94